Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521997 · ClinicalTrials.gov registry record · Phase 2
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Not yet
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT05521997 is a Phase 2 study that has not yet begun recruiting, run by Washington University School of Medicine. The registered enrollment target is 42 participants.
The verdict
NCT05521997, a Phase 2 study, has not yet begun recruiting, sponsored by Washington University School of Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Interventions
- DRUG Cisplatin
- DRUG Telaglenastat
- RADIATION Radiation treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-07-31 |
| Est. Completion | 2032-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05521997
The ClinicalTrials.gov registry entry for NCT05521997 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT05521997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05521997 about?
NCT05521997 is a clinical study titled "Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer". Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
What is the current status of trial NCT05521997?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2026-07-31. Estimated completion is 2032-10-07.
What interventions are being tested in trial NCT05521997?
The interventions under investigation include: Cisplatin (DRUG), Telaglenastat (DRUG), Radiation treatment (RADIATION).
Who is sponsoring clinical trial NCT05521997?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.